Eli Lilly launches Foundayo pill
Eli Lilly launched Foundayo, a newly approved weight‑loss pill, in the U.S. after FDA approval, expanding the market of pharmacological obesity treatments. The product rollout adds another FDA‑cleared option to the competitive GLP‑1 landscape and could shift prescribing and retail pharmacy dynamics. (Twitter / WSJ)
A weight-loss drug that used to mean a weekly injection now comes as a once-daily pill, and Eli Lilly says Foundayo is shipping across the United States through LillyDirect, telehealth providers, and retail pharmacies nationwide as of April 9. The brand name is Foundayo, and the drug inside it is orforglipron. (lilly.com) Foundayo works by copying the signal of a gut hormone called glucagon-like peptide-1, which tells the brain and stomach that you have eaten enough. That same hormone pathway is what made injectable drugs like Wegovy and Zepbound so popular over the last few years. (fda.gov) The practical change is not just “pill instead of shot.” The Food and Drug Administration says Foundayo can be taken once daily with or without food, and Lilly says it does not come with the food-and-water timing rules that shaped earlier oral drugs in this category. (fda.gov) (lilly.com) The Food and Drug Administration approved Foundayo on April 1, 2026 for adults with obesity, or adults with overweight plus at least one weight-related medical condition, alongside diet and physical activity. The agency said the review took 50 days under its Commissioner’s National Priority Voucher pilot, making it the fastest approval of a new molecular entity since 2002. (fda.gov) In the main late-stage obesity trial, people without diabetes who took the highest studied dose of orforglipron lost an average of 12.4% of body weight over 72 weeks, or about 27.3 pounds. The study enrolled 3,127 patients and compared three daily doses against placebo. (nejm.org) This does not replace the strongest injectables on raw weight loss. It gives Lilly something different to sell: a pill for people who do not want needles, cold-chain shipping, or injection training. (apnews.com) (biopharmadive.com) The launch also turns the obesity market into a pill fight, not just a shot fight. Reuters reported that Novo Nordisk’s oral Wegovy was approved in December 2025 and launched in the United States in January 2026, giving Novo a short head start before Lilly arrived. (reuters.com) (drugs.com) Price is part of the launch strategy. Lilly said Foundayo starts at $25 a month for some commercially insured patients and $149 a month for self-pay patients, which is far below the list prices that made earlier obesity drugs hard to afford without coverage. (lilly.com) Doctors will still treat it like a serious prescription drug, not a casual diet pill. The Food and Drug Administration label carries a boxed warning about thyroid C-cell tumors, says patients should not combine it with another glucagon-like peptide-1 drug, and lists pancreatitis and severe gastrointestinal reactions among key risks. (fda.gov) What Lilly is really launching here is a simpler front door into the same obesity-drug market it already attacked with Zepbound. If patients can get a prescription filled at a regular pharmacy for a daily pill instead of learning injections, the next phase of the weight-loss boom may look a lot more like picking up blood-pressure medicine than starting a specialty biologic. (reuters.com) (lilly.com)
